Welcome
Support Centre
04 July 2009 
ISRCTN Register - International Standard Randomized Controlled Trial Number
Trial registration
Unique identification scheme
International databases
home  |   my details  |   ISRCTN Register  |   mRCT  |   UKCTG  |   links  |   information  |   press
Find trials
ISRCTN Register
tips on searching

Registration
New application
Updating record

Information
introduction
governing board
ISRCTN FAQs
data set
letter of agreement
request information
guidance notes

[ Print-friendly version ]
Ultrasound therapy for plantar fasciitis. A double blind randomised placebo controlled trial
ISRCTN ISRCTN87769578
ClinicalTrials.gov identifier
Public title Ultrasound therapy for plantar fasciitis. A double blind randomised placebo controlled trial
Scientific title
Acronym N/A
Serial number at source N0544093542
Study hypothesis Ultrasound in plantar fasciitis.
Ethics approval Not provided at time of registration
Study design Randomised controlled trial
Countries of recruitment United Kingdom
Disease/condition/study domain Musculoskeletal Diseases: Plantar fasciitis
Participants - inclusion criteria 200 (PROJ)
Participants - exclusion criteria Not provided at time of registration
Anticipated start date 12/10/2000
Anticipated end date 12/10/2003
Status of trial Completed
Patient information material
Target number of participants 200
Interventions To evaluate the effects of ultrasound in the treatment of plantar fasciitis. Adult subjects with plantar fasciitis will be randomised to receive either ultrasound (US) or sham (S) therapy. In the US group pulsed ultrasound will be delivered at a standardised dosage, initially five times weekly for 3 weeks, then three times weekly for 3 weeks. A single machine will be used and calibrated twice daily. The patient, assessor and treating clinician will all be blinded. Outcome measures will be recorded at 6 weeks and at 4 months from baseline. These will include an ankle and foot score and pain (primary measures), isokinetic strength of ankle plantar flexion and dorsifexion, flexibility, inflammation (thermographic score), quality of life and general health status, a summary item of status of the injury and a follow up transition item.
Primary outcome measure(s) Not provided at time of registration
Secondary outcome measure(s) Not provided at time of registration
Sources of funding Cambridge Consortium - Addenbrookes
Trial website
Publications
Contact name Dr  Cathy  Speed
  Address Box No 204
Department of Rheumatology
Addenbrooke's NHS Trust
Hills Road
  City/town Cambridge
  Zip/Postcode CB2 2QQ
  Country United Kingdom
  Tel +44 01223 586518
  Fax +44
  Email cas50@medschl.cam.ac.uk
Sponsor Record provided by the NHS Trusts Clinical Trials Register - Department of Health (UK)
  Address The Department of Health
Richmond House
79 Whitehall
  City/town London
  Zip/Postcode SW1A 2NL
  Country United Kingdom
  Tel +44 (0)20 7307 2622
  Fax +44 (0)20 7307 2623
  Email dhmail@doh.gsi.org.uk
  Sponsor website: http://www.doh.gov.uk
Date applied 12/09/2003
Last edited 03/01/2006
Date ISRCTN assigned 12/09/2003
Submit your trial protocol Submit to Trials journal
© ISRCTN


BioMed Central